ArticleBlood advances2026
Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Macrophage heterogeneity in human secondary lymphoid organs.Clinical science (London, England : 1979) · 2026Review
- Plasma proteomic signatures of cellular aging predict human disease.Nature medicine · 2026Article
- Cellular Aging Signatures in the Plasma Proteome Record Human Health and Disease.bioRxiv : the preprint server for biology · 2026Article
- Spatial immune ecosystems and therapy resistance in large B-cell lymphoma: from single-cell multi-omics to immunotherapy-matched validation.Frontiers in immunology · 2026Review
- Deceptive initial presentation of systemic DLBCL with CNS progression following Oligometabolic PET/CT: case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractDiffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the 2 most common B-cell lymphomas and are characterized by a dynamic crosstalk between tumor B cells and a heterogeneous, tumor-supportive microenvironment, such as immune, endothelial, and stromal components. Despite their recognized impact on the pathogenesis and prognosis of B-cell lymphoma, tumor-associated macrophages (TAM) have not been extensively explored in these diseases. In this study, we investigated mononuclear phagocyte (MNP) heterogeneity at the single-cell level and the activation profile of MNP, stromal, and endothelial compartments, in B-cell lymphoma lymph nodes compared to reactive secondary lymphoid organs. This was achieved using a combination of mass cytometry, single-cell RNA sequencing, in silico and spatial imaging approaches. Our findings revealed a lymphoma-specific pattern of TAM and blood endothelial cell (BEC) coactivation. Furthermore, we identified in DLBCL a spatial interaction between Annexin A1 (ANXA1)-expressing BEC and formyl-peptide receptor (FPR1/2) and S100A9-expressing monocytes/macrophages. This crosstalk is associated with an immunosuppressive tumor microenvironment and an adverse prognosis in patients with DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.